BMS Projects 2022 Growth Even With $3bn Hit From Revlimid, Abraxane Generics
Current Blockbusters, New Products To Make Up Difference
Bristol executives reiterated the company’s aggressive revenue growth expectations while outlining the impact Revlimid generics will have in Europe, Japan and – to a limited extent – in the US.
